alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 8,876–8,900 of 10,985 studies · free to read (page 356 of 440) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

MicroRNA-193b is a regulator of amyloid precursor protein in the blood and cerebrospinal fluid derived exosomal microRNA-193b is a biomarker of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Molecular medicine reports 2014-08-12

Amyloid precursor protein (APP) has an important function in the generation of Alzheimer's disease (AD). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Molecular medicine (Cambridge, Mass.) 2001-09-01

We suggest that the APP23 Tg mouse may develop an earlier blockage in A beta clearance than the Tg2576 mice, resulting in a more severe accumulation of A beta in the perivascular drainage pathways and in the brain. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Transcranial Color-Coded Doppler Cerebral Hemodynamics Following Aerobic Exercise Training: Outcomes From a Pilot Randomized Clinical Trial

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal for vascular ultrasound : JVU 2022-09-06

This study did not demonstrate evidence of a significant change in the MFV in the middle cerebral arteries or evidence of a significant change in the PI between UPA and EPA groups. 3 key findings →

Participants: 12 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

The efficacy and safety of hachimijiogan for mild Alzheimer disease in an exploratory, open standard treatment controlled, randomized allocation, multicenter trial: A study protocol

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Medicine 2020-09-01

This is the first trial of Kampo medicine designed to examine the efficacy of HJG for the cognitive dysfunction of patients with mild AD. 5 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

The impact of inflammation on cognitive function in older adults: implications for healthcare practice and research

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses 2012-08-01

Accumulating evidence suggests that levels of inflammation, an immune response, increase with age throughout the body and the brain. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management

✓ Peer-reviewed alzhub usefulness score 40 out of 100. CNS drugs 2010-05-01

Frontotemporal lobar degeneration (FTLD) is a clinically and pathologically heterogeneous syndrome, characterized by progressive decline in behaviour or language associated with degeneration of the frontal and anterior temporal lobes. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Medial temporal structures relate to memory impairment in Alzheimer's disease: an MRI volumetric study

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of neurology, neurosurgery, and psychiatry 1997-08-01

The presence of perihippocampal damage involving the amygdala proper, its surrounding cortex, and the subiculum further increased the severity of memory impairment attributable to hippocampal damage in Alzheimer's disease. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Diagnosis of intracranial vasculitis: a multi-disciplinary approach

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of neuropathology and experimental neurology 1998-01-01

Intracranial vasculitis, or primary angiitis of the central nervous system (PACNS), is an uncommon, often fatal disorder that frequently responds to aggressive immunosuppressive therapy. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Perceptions of dementia and use of services in minority ethnic communities: a scoping exercise

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Health & social care in the community 2016-06-09

Despite the rapidly ageing population and a predicted sevenfold increase in the prevalence of dementia in minority ethnic communities, people from these communities remain under-represented in specialist dementia services. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Racial and ethnic disparities in the treatment of dementia among Medicare beneficiaries

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The journals of gerontology. Series B, Psychological sciences and social sciences 2008-09-01

After adjusting for demographics, socioeconomics, health care access and utilization, comorbidities, and service year, we found that anti-dementia medication use was approximately 30% higher among non-Hispanic Whites compared to other racial/ethnic groups (PR=0.73, 95% confidence interval [CI]=0.59, 0.91). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Role of Quantitative EEG in the Diagnosis of Neuropsychiatric Disorders

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of medicine and life 2020-01-01

Quantitative electroencephalography (QEEG) is a modern type of electroencephalography (EEG) analysis that involves recording digital EEG signals which are processed, transformed, and analyzed using complex mathematical algorithms. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Predicting Prodromal Alzheimer's Disease in Subjects with Mild Cognitive Impairment Using Machine Learning Classification of Multimodal Multicenter Diffusion-Tensor and Magnetic Resonance Imaging Data

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of neuroimaging : official journal of the American Society of Neuroimaging 2015-01-28

Our results suggest that DTI data provide better prediction accuracy than GM volume in predementia AD. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The comprehensive process model of engagement

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2011-10-01

Personal attributes, environmental factors, and stimulus characteristics all contribute to the level and nature of engagement, with a secondary finding being that exposure to any stimulus elicits engagement in persons with dementia. 5 key findings →

Participants: 24 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Speech monitoring skills in Alzheimer's disease, Parkinson's disease, and normal aging

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Brain and language 1992-01-01

We examined the abilities of 15 patients with dementia of the Alzheimer type (DAT), 22 patients with Parkinson's Disease (PD), and 141 healthy subjects (ranging in age from 30 to 79 years) to detect and correct their own speech errors. 1 key finding →

Participants: 15 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Parkinsonism and frontotemporal dementia: the clinical overlap

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of molecular neuroscience : MN 2011-09-03

Frontotemporal dementia is commonly associated with parkinsonism in several sporadic (i.e., progressive supranuclear palsy, corticobasal degeneration) and familial neurodegenerative disorders (i.e., frontotemporal dementia associated with parkinsonism and MAPT or progranulin mutations in chromosome 17). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed